Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Rennes University Hospital Bayer Wyeth Farmades, Italy |
---|---|
Information provided by: | Rennes University Hospital |
ClinicalTrials.gov Identifier: | NCT00219908 |
The aim of the study is to determine whether a therapeutic strategy combining mitoxantrone and interferon beta1b can delay disease progression of at least one point on EDSS scale in patients with clinically very active relapsing-remitting multiple sclerosis.
Condition | Intervention | Phase |
---|---|---|
Relapsing-Remitting Multiple Sclerosis |
Drug: Mitoxantrone |
Phase II |
Study Type: | Interventional |
Study Design: | Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis: Induction Treatment With Mitoxantrone Followed by Long-Term Treatment With Interferon-beta1b |
Estimated Enrollment: | 124 |
Study Start Date: | July 1999 |
Estimated Study Completion Date: | June 2006 |
Ages Eligible for Study: | 18 Years to 45 Years |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
France | |
CHU Purpan | |
Toulouse, France, 31059 | |
Pierre Weitheimer Hospital | |
Lyon, France, 69394 | |
CHU Pitié-Salpétrière | |
Paris, France, 75013 | |
Tenon Hospital | |
Paris, France, 759170 | |
CHU Henri Mondor | |
Creteil, France, 94000 | |
CHU Strasbourg | |
Strasbourg, France, 67000 | |
CHU Hôpital Central | |
Nancy, France, 54035 | |
Hôpital Cote de Nacre | |
Caen, France, 14033 | |
Institut Catholique de Lille | |
Lomme, France, 59462 | |
Centre Fondation Rotschild | |
Paris, France, 75019 | |
CHU TIMONE | |
Marseille, France, 13385 | |
CHU Limoges | |
Limoges, France, 87042 | |
Hôpital Saint-Anne | |
Paris, France, 75014 | |
Centre Guy de Chauliac | |
Montpellier, France, 34295 | |
Hôpital Général | |
Dijon, France, 21033 | |
Hôpital Gabriel Montpied | |
Clermont-Ferrand, France, 63003 | |
CHU | |
Nice, France, 06000 | |
Italy | |
Fondazionz SAN Raffaele del monte tabor | |
Milano, Italy, 20132 | |
Dipartimento di Scienze Neurologiche e Psichiatriche | |
Firenze, Italy, 50134 | |
Hospedal Civile | |
Gallarate, Italy, 21013 | |
Neuroriabilitazione dell'Università | |
Genova, Italy, 16132 | |
Clinica Neurologica Università di Torino | |
Torino, Italy, 10126 | |
Psichiatriche dell'Università di Bari, Policlinico | |
Bari, Italy, 70122 |
Study Director: | Gilles EDAN, Professor | CHU Rennes |
Study ID Numbers: | 981166 |
Study First Received: | September 16, 2005 |
Last Updated: | December 21, 2005 |
ClinicalTrials.gov Identifier: | NCT00219908 History of Changes |
Health Authority: | France: Afssaps - French Health Products Safety Agency |
Multiple sclerosis Mitoxantrone Methylprednisolone Interferon beta1b |
Relapse MRI EDSS |
Anti-Infective Agents Autoimmune Diseases Immunologic Factors Demyelinating Diseases Methylprednisolone Interferons Adjuvants, Immunologic Interferon-beta Sclerosis |
Multiple Sclerosis, Relapsing-Remitting Antiviral Agents Multiple Sclerosis Interferon beta-1b Demyelinating Autoimmune Diseases, CNS Peripheral Nervous System Agents Analgesics Mitoxantrone Autoimmune Diseases of the Nervous System |
Anti-Infective Agents Immunologic Factors Antineoplastic Agents Physiological Effects of Drugs Multiple Sclerosis, Relapsing-Remitting Pathologic Processes Multiple Sclerosis Sensory System Agents Therapeutic Uses Analgesics Autoimmune Diseases of the Nervous System Autoimmune Diseases Immune System Diseases |
Demyelinating Diseases Nervous System Diseases Interferon-beta Adjuvants, Immunologic Sclerosis Antiviral Agents Pharmacologic Actions Interferon beta-1b Demyelinating Autoimmune Diseases, CNS Mitoxantrone Peripheral Nervous System Agents Central Nervous System Agents |